JP2022527189A5 - - Google Patents
Info
- Publication number
- JP2022527189A5 JP2022527189A5 JP2021557924A JP2021557924A JP2022527189A5 JP 2022527189 A5 JP2022527189 A5 JP 2022527189A5 JP 2021557924 A JP2021557924 A JP 2021557924A JP 2021557924 A JP2021557924 A JP 2021557924A JP 2022527189 A5 JP2022527189 A5 JP 2022527189A5
- Authority
- JP
- Japan
- Prior art keywords
- fgfr3
- gene mutations
- fgfr
- fgfr gene
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025072308A JP2025156297A (ja) | 2019-03-29 | 2025-04-24 | 尿路上皮癌の治療のためのfgfrチロシンキナーゼ阻害剤 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19166428 | 2019-03-29 | ||
| EP19166428.3 | 2019-03-29 | ||
| EP19188971.6 | 2019-07-30 | ||
| EP19188971 | 2019-07-30 | ||
| PCT/US2020/025166 WO2020205493A1 (en) | 2019-03-29 | 2020-03-27 | Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025072308A Division JP2025156297A (ja) | 2019-03-29 | 2025-04-24 | 尿路上皮癌の治療のためのfgfrチロシンキナーゼ阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022527189A JP2022527189A (ja) | 2022-05-31 |
| JP2022527189A5 true JP2022527189A5 (cg-RX-API-DMAC7.html) | 2023-04-03 |
| JP7747521B2 JP7747521B2 (ja) | 2025-10-01 |
Family
ID=70296138
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021557924A Active JP7747521B2 (ja) | 2019-03-29 | 2020-03-27 | 尿路上皮癌の治療のためのfgfrチロシンキナーゼ阻害剤 |
| JP2025072308A Pending JP2025156297A (ja) | 2019-03-29 | 2025-04-24 | 尿路上皮癌の治療のためのfgfrチロシンキナーゼ阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025072308A Pending JP2025156297A (ja) | 2019-03-29 | 2025-04-24 | 尿路上皮癌の治療のためのfgfrチロシンキナーゼ阻害剤 |
Country Status (15)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12277100B2 (en) * | 2019-09-12 | 2025-04-15 | Life Spectacular, Inc. | Maintaining user privacy of personal, medical, and health care related information in recommendation systems |
| WO2022243467A1 (en) * | 2021-05-19 | 2022-11-24 | Janssen Pharmaceutica Nv | Fgfr tyrosine kinase inhibitors for the treatment of advanced solid tumors |
| EP4719420A1 (en) * | 2023-05-24 | 2026-04-08 | Janssen Pharmaceutica NV | Treatment of locally advanced or metastatic urothelial carcinoma with erdafinitib |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
| CA2744096C (en) | 1996-07-31 | 2013-07-30 | Laboratory Corporation Of America Holdings | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| EP2270000B1 (en) | 2005-05-23 | 2015-07-29 | Novartis AG | Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts |
| US8163923B2 (en) | 2007-03-14 | 2012-04-24 | Advenchen Laboratories, Llc | Spiro substituted compounds as angiogenesis inhibitors |
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| EP4223770A3 (en) | 2012-11-05 | 2023-10-18 | Foundation Medicine, Inc. | Novel fusion molecules and uses thereof |
| CA2898326C (en) | 2013-01-18 | 2022-05-17 | Foundation Medicine, Inc. | Methods of treating cholangiocarcinoma |
| US10736900B2 (en) | 2014-03-26 | 2020-08-11 | Astex Therapeutics Ltd | Combinations of an FGFR inhibitor and an IGF1R inhibitor |
| JO3512B1 (ar) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز |
| BR112016022056B1 (pt) | 2014-03-26 | 2023-04-11 | Astex Therapeutics Limited | Combinação, composição farmacêutica, uso de uma combinação ou uma composição farmacêutica, e, produto farmacêutico |
| SG11201702381QA (en) | 2014-09-26 | 2017-04-27 | Janssen Pharmaceutica Nv | Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor |
| TWI719960B (zh) | 2015-02-10 | 2021-03-01 | 英商阿斯迪克治療公司 | 新穎組成物 |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| EP3365335B1 (en) | 2015-10-23 | 2024-02-14 | Array Biopharma, Inc. | 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases |
| CN110785184A (zh) * | 2017-02-06 | 2020-02-11 | 雷尼尔医疗公司 | 用于治疗癌症的方法,组合物和试剂盒 |
| CA3049737A1 (en) * | 2017-02-06 | 2018-08-09 | Janssen Pharmaceutica Nv | Cancer treatment |
| JOP20190280A1 (ar) * | 2017-06-02 | 2019-12-02 | Janssen Pharmaceutica Nv | مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية |
| MA47408B1 (fr) | 2017-12-20 | 2023-08-31 | Janssen Pharmaceutica Nv | Traitement du cancer |
| KR20210064274A (ko) | 2018-09-21 | 2021-06-02 | 얀센 파마슈티카 엔.브이. | 담관암종의 치료 |
| BR112021015686A2 (pt) | 2019-02-12 | 2021-10-26 | Janssen Pharmaceutica N.V. | Tratamento de câncer |
| US20220175768A1 (en) | 2019-03-29 | 2022-06-09 | Janssen Pharmaceutica Nv | Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma |
-
2020
- 2020-03-27 MX MX2021011926A patent/MX2021011926A/es unknown
- 2020-03-27 MA MA055522A patent/MA55522A/fr unknown
- 2020-03-27 KR KR1020217034721A patent/KR20210145211A/ko not_active Ceased
- 2020-03-27 US US17/599,729 patent/US12691112B2/en active Active
- 2020-03-27 EP EP20720283.9A patent/EP3946341A1/en active Pending
- 2020-03-27 SG SG11202109902S patent/SG11202109902SA/en unknown
- 2020-03-27 BR BR112021019446A patent/BR112021019446A2/pt unknown
- 2020-03-27 CA CA3130460A patent/CA3130460A1/en active Pending
- 2020-03-27 CN CN202080025860.4A patent/CN113645974A/zh active Pending
- 2020-03-27 WO PCT/US2020/025166 patent/WO2020205493A1/en not_active Ceased
- 2020-03-27 PH PH1/2021/552342A patent/PH12021552342A1/en unknown
- 2020-03-27 JP JP2021557924A patent/JP7747521B2/ja active Active
- 2020-03-27 AU AU2020253827A patent/AU2020253827B2/en active Active
-
2021
- 2021-09-26 IL IL286729A patent/IL286729A/en unknown
- 2021-09-26 JO JOP/2021/0266A patent/JOP20210266A1/ar unknown
-
2025
- 2025-04-24 JP JP2025072308A patent/JP2025156297A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lin et al. | Zinc supplementation to improve mucositis and dermatitis in patients after radiotherapy for head-and-neck cancers: a double-blind, randomized study | |
| Aapro et al. | Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer | |
| JP2022527482A5 (cg-RX-API-DMAC7.html) | ||
| TW201615221A (zh) | 炎症用藥臨床新應用 | |
| JP2023113650A5 (cg-RX-API-DMAC7.html) | ||
| Abdallah et al. | The AMPK modulator metformin as adjunct to methotrexate in patients with rheumatoid arthritis: A proof-of-concept, randomized, double-blind, placebo-controlled trial | |
| CN107308141B (zh) | 石斛酚在制备预防和治疗动脉粥样硬化药物中的应用 | |
| EP4313043A1 (en) | Treatment of hidradenitis suppurativa with orismilast | |
| Klein et al. | Off‐label use of fumarate therapy for granulomatous and inflammatory skin diseases other than psoriasis vulgaris: a retrospective study | |
| JP2022521173A5 (cg-RX-API-DMAC7.html) | ||
| Cornu et al. | No effect of a homoeopathic combination of Arnica montana and Bryonia alba on bleeding, inflammation, and ischaemia after aortic valve surgery | |
| JP2023513298A5 (cg-RX-API-DMAC7.html) | ||
| Sarzi-Puttini et al. | Clinical benefits of ibuprofen arginine: a narrative review | |
| Kalogirou et al. | mTOR inhibitor-associated stomatitis (mIAS) in three patients with cancer treated with everolimus | |
| EP0074426B1 (en) | Pharmaceutical oral dosage forms of an active agent capable of forming or releasing bicarbonate ions | |
| Barr et al. | Cation metabolism during propofol sedation with and without EDTA in patients with impaired renal function | |
| CN115645395B (zh) | Myls22在制备用于治疗急性肝损伤疾病药物中的应用 | |
| CN110179773A (zh) | 石斛酚在制备预防和治疗慢性肾小球疾病药物中的应用 | |
| WILSON | Dialysis and psoriasis | |
| JP2023542296A5 (cg-RX-API-DMAC7.html) | ||
| AU2024235111B2 (en) | 2-hydroxy-octadecene-9-cis-oate for use in the treatment of oncological pathologies and neuropathic pain | |
| Hernández-Cruz et al. | OP0123 Safety profile of JAK-inhibitors versus TNF-inhibitors in real-world clinical practice: data from a multicenter register | |
| Robson et al. | Dialysis in scleroderma | |
| EP4452275B1 (en) | Combination of cisplatin and elimusertib for the treatment of pediatric liver cancers | |
| Li et al. | ABS1104 Efficacy and Safety of Tofacitinib Combined with Iguratimod in the Treatment of Rheumatoid Arthritis Patients with Poor Response to Csdmards: A Multicenter, Prospective, Cohort Study |